24/7 Market News Snapshot 23 July, 2025 – Replimune Group, Inc. (NASDAQ:REPL)
DENVER, Colo., 23 July, 2025 (www.247marketnews.com) – (NASDAQ:REPL) are discussed in this article.
Replimune Group, Inc. (NASDAQ:REPL) has experienced significant market activity today, with its stock price opening at $2.74 and surging to $3.285, representing a 17.11% rise from the previous close of $2.805. The notable trading volume of approximately 41.71 million shares reflects heightened investor interest, indicating a potential breakout. Analysts observe that the current price is positioned above both the opening and last closing prices, which fosters optimistic market sentiment. Key resistance levels are contemplated around $3.30, while support is identified closer to the $2.80 mark. Investors are advised to monitor for further upward movement but to remain cautious should trading volumes decline.
In parallel, Replimune is under scrutiny as Bleichmar Fonti & Auld LLP announces an investigation related to possible violations of federal securities laws following significant developments concerning its lead product, RP1, aimed at melanoma treatment. The company’s announcement on June 6, 2024, detailing positive top-line results from the Phase 1/2 IGNYTE trial, preceded the filing of a biologics license application (BLA) with the FDA. However, recent FDA correspondence has revealed major concerns regarding the trial’s design and execution.
On July 22, 2025, Replimune disclosed receipt of a Complete Response Letter from the FDA, which indicated that the IGNYTE trial was not considered a well-controlled investigation. This response highlighted the varied characteristics of the patient population involved, undermining the trial’s credibility. As a consequence, Replimune’s stock value plummeted more than 75%. Investors affected during this tumultuous period may have avenues for legal recourse as the investigation unfolds. Stakeholders are encouraged to remain vigilant and informed as developments in this case progress.